Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration.

Navarro-García JA, Rodríguez-Sánchez E, Aceves-Ripoll J, Abarca-Zabalía J, Susmozas-Sánchez A, González Lafuente L, Bada-Bosch T, Hernández E, Mérida-Herrero E, Praga M, Ruilope LM, Ruiz-Hurtado G.

Nutrients. 2019 Nov 17;11(11). pii: E2809. doi: 10.3390/nu11112809.

2.

Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors.

RodrÍguez-SÁnchez E, Navarro-GarcÍa JA, Aceves-Ripoll J, GonzÁlez-Lafuente L, Corbacho-Alonso N, Martinez P, Calvo-Bonacho E, Alvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G.

Transl Res. 2019 Oct;212:54-66. doi: 10.1016/j.trsl.2019.06.002. Epub 2019 Jun 29.

PMID:
31295436
3.

Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes.

Navarro-García JA, Delgado C, Fernández-Velasco M, Val-Blasco A, Rodríguez-Sánchez E, Aceves-Ripoll J, Gómez-Hurtado N, Bada-Bosch T, Mérida-Herrero E, Hernández E, Praga M, Salguero R, Solís J, Arribas F, Delgado JF, Bueno H, Kuro-O M, Ruilope LM, Ruiz-Hurtado G.

Nephrol Dial Transplant. 2019 Nov 1;34(11):1864-1875. doi: 10.1093/ndt/gfy392.

PMID:
30629224
4.

Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients.

Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, Álvarez-Llamas G, Segura J, Barderas MG, Ruilope LM, Ruiz-Hurtado G.

Nefrologia. 2019 Mar - Apr;39(2):184-191. doi: 10.1016/j.nefro.2018.08.009. Epub 2018 Dec 1. English, Spanish.

5.

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.

González-Blázquez R, Somoza B, Gil-Ortega M, Martín Ramos M, Ramiro-Cortijo D, Vega-Martín E, Schulz A, Ruilope LM, Kolkhof P, Kreutz R, Fernández-Alfonso MS.

Front Pharmacol. 2018 Oct 9;9:1131. doi: 10.3389/fphar.2018.01131. eCollection 2018.

6.

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G; ARRIVE Executive Committee.

Lancet. 2018 Sep 22;392(10152):1036-1046. doi: 10.1016/S0140-6736(18)31924-X. Epub 2018 Aug 26.

PMID:
30158069
7.

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.

Rossi GP, Seccia TM, Barton M, Danser AHJ, de Leeuw PW, Dhaun N, Rizzoni D, Rossignol P, Ruilope LM, van den Meiracker AH, Ito S, Hasebe N, Webb DJ.

J Hypertens. 2018 Mar;36(3):462-471. doi: 10.1097/HJH.0000000000001600. Review.

PMID:
29135628
8.

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society of Hypertension.

Rossi GP, Seccia TM, Barton M, Danser AHJ, de Leeuw PW, Dhaun N, Rizzoni D, Rossignol P, Ruilope LM, van den Meiracker AH, Ito S, Hasebe N, Webb DJ.

J Hypertens. 2018 Mar;36(3):451-461. doi: 10.1097/HJH.0000000000001599. Review.

PMID:
29120962
9.

Citric Acid Metabolism in Resistant Hypertension: Underlying Mechanisms and Metabolic Prediction of Treatment Response.

Martin-Lorenzo M, Martinez PJ, Baldan-Martin M, Ruiz-Hurtado G, Prado JC, Segura J, de la Cuesta F, Barderas MG, Vivanco F, Ruilope LM, Alvarez-Llamas G.

Hypertension. 2017 Nov;70(5):1049-1056. doi: 10.1161/HYPERTENSIONAHA.117.09819. Epub 2017 Sep 5.

PMID:
28874460
10.

Association Between Improvement in Cardiovascular Risk Profile and Changes in Sickness Absence: Results of the ICARIA Study.

Calvo-Bonacho E, Catalina-Romero C, Cabrera M, Fernández-Labandera C, Sánchez Chaparro MÁ, Brotons C, Ruilope LM.

Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):941-951. doi: 10.1016/j.rec.2017.02.017. Epub 2017 Mar 11. English, Spanish.

PMID:
28291729
11.

24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients.

Vinyoles E, de la Sierra A, Roso-Llorach A, Banegas JR, de la Cruz JJ, Gorostidi M, Segura J, Divisón JA, Ruíz-Hurtado G, Ruilope LM; Spanish ABPM Registry Investigators.

J Hypertens. 2017 May;35(5):1011-1018. doi: 10.1097/HJH.0000000000001268.

PMID:
28118277
12.

Adherence to the "Mediterranean Diet" in Spain and Its Relationship with Cardiovascular Risk (DIMERICA Study).

Abellán Alemán J, Zafrilla Rentero MP, Montoro-García S, Mulero J, Pérez Garrido A, Leal M, Guerrero L, Ramos E, Ruilope LM.

Nutrients. 2016 Oct 28;8(11). pii: E680.

13.

Investigational calcium channel blockers for the treatment of hypertension.

Tamargo J, Ruilope LM.

Expert Opin Investig Drugs. 2016 Nov;25(11):1295-1309. doi: 10.1080/13543784.2016.1241764. Review.

PMID:
27696904
14.

Second denervation in a patient with resistant hypertension.

Prado JC, Salado D, Ruilope LM, Segura J.

Clin Res Cardiol. 2016 Oct;105(10):880-3. doi: 10.1007/s00392-016-0997-6. Epub 2016 Jun 8. No abstract available.

PMID:
27278635
15.

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, Silani V, Bilo G, Corrao G, Zambon A, Scotti L, Zhang X, Guan TR, Zhang Y, Zhang X, Berge E, Redon J, Narkiewicz K, Dominiczak A, Nilsson P, Viigimaa M, Laurent S, Agabiti-Rosei E, Wu Z, Zhu D, Rodicio JL, Ruilope LM, Martell-Claros N, Pinto F, Schmieder RE, Burnier M, Banach M, Cifkova R, Farsang C, Konradi A, Lazareva I, Sirenko Y, Dorobantu M, Postadzhiyan A, Accetto R, Jelakovic B, Lovic D, Manolis AJ, Stylianou P, Dicker D, Wei G, Xu C, Xie H, Coca A, O'Brien J, Ford G; ESH-CHL-SHOT trial investigators.

J Hypertens. 2016 Mar;34(3):393-6. doi: 10.1097/HJH.0000000000000853. No abstract available.

PMID:
26780185
16.

[Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].

Guijarro C, Ruilope LM.

Med Clin (Barc). 2015 Jul 20;145(2):67-9. doi: 10.1016/j.medcli.2015.04.007. Epub 2015 May 23. Spanish. No abstract available.

PMID:
26004275
17.

Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.

Ruiz-Hurtado G, Ruilope LM.

Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):126-31. doi: 10.1093/ehjcvp/pvu023. Epub 2015 Mar 20. Review. Erratum in: Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):217.

PMID:
27533982
18.

[Renal denervation as treatment of resistant hypertension].

Galve E, Martell-Claros N, Camafort-Babkowski M; Grupo de consenso español sobre denervación renal.

Med Clin (Barc). 2015 Aug 7;145(3):131-5. doi: 10.1016/j.medcli.2014.12.011. Epub 2015 Mar 4. Spanish. No abstract available.

PMID:
25746610
19.

Impact of the new American and British guidelines on the management and treatment of dyslipidemia in a Spanish working population.

Brotons C, Calvo-Bonacho E, Moral I, García-Margallo MT, Cortés-Arcas MV, Puig M, Vázquez-Pirillo G, Ruilope LM.

Rev Esp Cardiol (Engl Ed). 2014 Nov;67(11):906-11. doi: 10.1016/j.rec.2014.06.018. Epub 2014 Sep 30.

PMID:
25278212
20.

Reply: contribution of the ABP-International study to the definition of night-time tachycardia.

Vinyoles E, Sierra Ade L, Roso A, Cruz JJ, Gorostidi M, Segura J, Banegas JR, Martell-Claros N, Ruilope LM; Spanish ABPM Registry of Investigators.

J Hypertens. 2014 Oct;32(10):2101. doi: 10.1097/HJH.0000000000000335. No abstract available.

PMID:
25186533

Supplemental Content

Loading ...
Support Center